Female and male patients aged 18 years and older presenting within 5 days (preferably 72 hours) after pain onset with the main diagnosis of STEMI, NSTEMI, or unstable angina were included in the registry (4,5). Included patients had symptoms compatible with angina pectoris (chest pain, dyspnea) and fulfilled at least one of the following criteria: (i.) persistent ST-segment elevation or depression, T inversion or dynamic ECG changes, new left bundle branch block; (ii.) evidence of positive troponin with rise and/or fall in serial troponin levels; (iii.) known coronary artery disease (specified as status after myocardial infarction, coronary artery bypass graft surgery, or PCI) or newly documented ≥ 50% stenosis of an epicardial coronary artery during the initial catheterization. Exclusion criteria were severe physical disability, inability to comprehend study, and estimated life expectancy less than 1 year (due to non-cardiac reasons).
were eligible for randomization in the presence of at least one culprit lesion in the infarct vessel (6) (7) (8) .
Exclusion criteria were presence of mechanical complications of acute myocardial infarction, known allergy to any study medication, use of vitamin K-antagonists, planned surgery unless dual anti-platelet therapy could be maintained throughout the peri-surgical period, history of bleeding diathesis or known coagulopathy, pregnancy, participation in another trial before reaching the primary endpoint, inability to provide informed consent, and non-cardiac co-morbid conditions with life expectancy below 1 year.
Definition of myocardial infarction
The diagnosis of spontaneous (>48 hours post index event) Q-wave myocardial infarction required new pathological Q waves in two or more contiguous ECG leads. The diagnosis of spontaneous non-Q wave MI required documented biomarker elevations consisting of 1) CK-MB >1*URL, or 2) in the absence of CK-MB, standard troponin elevations >1*URL, or 3) in the absence of standard troponin high sensitivity troponin>1*URL. The appropriate enzyme data were considered in aggregate with clinical parameters suggesting evidence of myocardial ischemia based on symptoms, electrocardiographic changes, cardiac imaging findings or new regional wall motion abnormalities.
Peri-procedural myocardial infarction was adjudicated according to three scenarios as described below: Data only available for patients included in the SPUM-ACS registry. Data are summarized as mean ± standard deviation, median (25%-75% interquartile range) or count (%). *Defined as estimated glomerular filtration rate <60 ml/min/1,73m² using the Cockcroft-Gault formula.
BMI indicates body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention. Figure S1 . Risk of bleeding in relation to early prasugrel cessation: crossover (n=131); discontinuation (n=67); and disruption (n=54). Presented are numbers of observed events (from Kaplan-Meier estimate), expected events, hazard ratios and respective 95% confidence intervals (CI). Figure S2 . Results of time-dependent Cox model analyses for the risk of adverse clinical outcomes following early prasugrel cessation (crossover: n=107; discontinuation; n=53; disruption: n=36) in a sensitivity analysis including only patients enrolled in the observational registries (Bern PCI Registry and SPUM-ACS study; n=1,346). Presented are numbers of observed events (from KaplanMeier estimate), expected events, hazard ratios (HRs) and respective 95% confidence intervals (CI). The observed versus expected number of events are presented for each period, where expected numbers were calculated as number of events divided by the HR (compared to the reference of being on prasugrel treatment).
